Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Palatin Technologies Inc
PTN
Healthcare
Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus...
primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSEAM:PTN)
New Post
View:
Posts & Comments
Threaded Posts
(271)
•••
whytestocks
X
Post by
whytestocks
on Nov 14, 2024 8:02pm
Palatin Reports First Quarter Fiscal Year 2025 Operating/Fin
News; $PTN Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPalatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire Obesity programs: Core focus
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Nov 08, 2024 3:00pm
Palatin to Report First Quarter Fiscal Year 2025 Results; Te
Breaking News: $PTN Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024Palatin to Report First Quarter Fiscal Year 2025 Results
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(271)
•••
whytestocks
X
Post by
whytestocks
on Oct 01, 2024 12:00pm
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Fi
News; $PTN Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPalatin Reports Fourth
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Aug 22, 2024 4:15pm
First Patient Dosed in Phase 2 Clinical Study of Palatin's B
NEWS: $PTN First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityFirst Patient Dosed in Phase 2 Clinical
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Jun 21, 2024 10:15pm
Palatin Announces Exercise of Warrants for Approximately $6.
Just In: $PTN Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Jun 12, 2024 4:30pm
Palatin Initiates Phase 2 Clinical Study of Bremelanotide fo
JUST IN: $PTN Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire
...more
(12)
•••
Bazvest
X
Post by
Bazvest
on Dec 23, 2020 12:20pm
News found December 22, 2020
Here is what I found. https://finance.yahoo.com/news/2-penny-stocks-poised-massive-181758413.html "... $3 price target implies room for a whooping 615% upside potential in the
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing